--GlaxoSmithKline and Reckitt Benckiser Group are the only companies that have submitted non-binding bids for Pfizer's consumer business after rival candidates walked away, Bloomberg reports unnamed sources as saying.

--Pfizer is planning to open a data room for Glaxo and Reckitt to start due-diligence work on the assets--which sources say could fetch between $15 billion and $20 billion--before filing their final offers, according to Bloomberg.

--Representatives for Glaxo and Reckitt declined to comment, Bloomberg says.

--Sanofi, Nestle and Johnson & Johnson contemplated offers before deciding not to pursue them, reports Bloomberg.

Full story: https://bloom.bg/2E4O251

Write to Barcelona editors at barcelonaeditors@dowjones.com

(END) Dow Jones Newswires

February 05, 2018 04:49 ET (09:49 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Grafico Azioni Reckitt Benckiser (LSE:RKT)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Reckitt Benckiser
Grafico Azioni Reckitt Benckiser (LSE:RKT)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Reckitt Benckiser